Literature DB >> 3456202

CA 125 surveillance and second-look laparotomy in ovarian carcinoma.

D B Atack, J A Nisker, H H Allen, E R Tustanoff, L Levin.   

Abstract

CA 125 was evaluated as a tumor marker in 31 patients undergoing treatment for ovarian carcinoma, 17 of whom had second-look laparotomies. At the time of second-look laparotomy, 14 patients had CA 125 values in the normal range. Six of these patients had a positive second-look laparotomy. Although normal CA 125 values do not obviate the need for second-look laparotomy in treatment planning, rising or falling trends reflected clinical disease progression or regression in 80% of the cases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3456202     DOI: 10.1016/0002-9378(86)90657-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

Review 1.  Limitations to the use of the CA-125 antigen level in ovarian cancer.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.075

2.  An Ovarian Cancer Tumor Marker, CA 125, Comes of Age.

Authors:  R E Buller; P J Disaia
Journal:  West J Med       Date:  1990-04

3.  Imaging of ovarian cancer with radiolabelled monoclonal antibodies.

Authors:  D L van Kranenburg; M J van Kroonenburgh; J B Trimbos; G J Fleuren; E K Pauwels
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

4.  Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.

Authors:  W Jäger; R Adam; L Wildt; N Lang
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

5.  Immunoscintigraphy using CA 125 antibodies in the management of ovarian cancer.

Authors:  J Brökelmann; A Bockisch; J Vogel; J Reinsberg; P Oehr; H J Biersack; D Krebs
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 6.  The use and potential of serum tumour markers, new and old.

Authors:  S E Bates
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

7.  Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer.

Authors:  Madhumita Chatterjee; Laura C Hurley; Nancy K Levin; Matthew Stack; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2017-12-06       Impact factor: 4.388

8.  Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody.

Authors:  C Y Lee; K W Chen; F S Sheu; A Tsang; K C Chao; H T Ng
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Peritoneal trauma releases CA125?

Authors:  C W Redman; S R Jones; D M Luesley; S E Nicholl; K Kelly; E J Buxton; K K Chan; G R Blackledge
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  Urinary gonadotropin fragment (UGF) measurements in the diagnosis and management of ovarian cancer.

Authors:  L A Cole; J H Nam
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.